GSK Reaps Emerging Market Benefits From Novartis Deal
This article was originally published in PharmAsia News
Executive Summary
GSK expects its recent transaction with Novartis, in particular the acquisition of the Swiss firm's vaccines business, to bolster its position across emerging markets, notably China.